Sphere Fluidics: biotherapeutics device attracts $7m investment

Innovate UK

February 15
09:02 2016

A Cambridge life sciences company that has developed a revolutionary system for single-cell analysis in the biopharmaceutical market, with support from Innovate UK, has secured private investment totalling $7 million.

Sphere Fluidics Ltds Cyto-Mine device promises to transform the discovery and development of biotherapeutics for treatment of cancer and inflammatory diseases and vaccine generation.

The company, based at the Babraham Research Campus in Cambridge, plans to launch a commercial version of Cyto-Mine later this year.

The funding round was led by an Asian corporate investor but included existing angel investors and funds such as 24Haymarket, Parkwalk Advisors and London Business Angels. A number of leading biopharmaceutical companies are also helping to fund development of the device.

Sphere Fluidics benefited in 2015 from Innovate UK funding for a feasibility study and a follow-on collaborative R&D project, together totalling 310,000.

Innovate UK funding for prototype

The company has just been awarded 340,000 for a further three-year collaborative R&D project.

Chief executive officer Dr Frank Craig said:

That early funding from Innovate UK allowed us to develop a prototype system with Medimmune for the biopharmaceutical market. It gave us real momentum and was also the hook that got private investors interested.

We are very pleased now to have ongoing investor support and also to extend our business activity and fund-raising success to Asia.

Cyto-Mine can perform millions of single-cell assays daily, offering up to a 100-fold improvement over conventional techniques. It achieves all this at lower capital and operational cost.

Dr Craig added: Our initial target market is biopharmaceuticals, but later we will also extend sales into other growing global markets, including synthetic biology, single cell therapy engineering, microbial analysis and single cancer cell diagnostics.

Related Articles


  1. We don't have any comments for this article yet. Why not join in and start a discussion.

Write a Comment

Your name:
Your email:

Post my comment

Recent Comments

Follow Us on Twitter

Share This

Enjoyed this? Why not share it with others if you've found it useful by using one of the tools below: